VRDN vs XENE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
VRDN · Viridian Therapeutics$29.96 ▼ 4.71%
XENE · Xenon Pharmaceuticals$37.04 ▼ 1.38%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- VRDN -6.5%
- XENE -11.9%
Head to head
| Metric | VRDN | XENE |
|---|---|---|
| Price | $29.96 | $37.04 |
| Change today | ▼ 4.71% | ▼ 1.38% |
| Market cap | $3.40B | $3.64B |
| Return, 3 months | +24.7% | -38.8% |
| Return, year to date | -3.7% | -17.4% |
| Return, 1 year | -1.3% | -10.0% |
| P/E (TTM) | – | – |
| P/B | 7.0 | 3.2 |
| P/E percentile vs own 5y | 12th | 97th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -63.5% | – |
| Net profit growth (YoY) | -192.5% | -21.5% |
| Gross margin | 94.1% | – |
| Operating margin | -1,781.4% | – |
| Net margin | -1,741.9% | – |
| Return on equity | -115.0% | -50.3% |
| Analyst target vs. price | +34.9% | +98.2% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 64 | 41 |
| 30-day volatility | 64.4% | 39.0% |
| Max drawdown, 1 year | -60.6% | -52.8% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- XENE is the largest of the group by market value.
- VRDN has returned the most over the past year.
- XENE has been the calmest stock over the last 30 days.